Cargando…

Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition

Type II transglutaminase (TG2) is a multifunctional protein that has recently been implicated as having a role in ECS cell survival. In the present study we investigate the role of TG2 in regulating epithelial mesenchymal transition (EMT) in ECS cells. Our studies show that TG2 knockdown or treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisher, Matthew L., Adhikary, Gautam, Xu, Wen, Kerr, Candace, Keillor, Jeffrey W., Eckert, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653023/ https://www.ncbi.nlm.nih.gov/pubmed/25971211

Ejemplares similares

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation
por: Adhikary, Gautam, et al.
Publicado: (2018)

Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype
por: Gates, Eric W. J., et al.
Publicado: (2023)

Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival
por: Kerr, Candace, et al.
Publicado: (2016)

Transglutaminase 2 maintains a colorectal cancer stem phenotype by regulating epithelial-mesenchymal transition
por: Ayinde, Oluseyi, et al.
Publicado: (2019)

Identification of a Population of Epidermal Squamous Cell Carcinoma Cells with Enhanced Potential for Tumor Formation
por: Adhikary, Gautam, et al.
Publicado: (2013)

A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2
por: Kim, Soo-Youl, et al.
Publicado: (2020)

Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells
por: Ayinde, Oluseyi, et al.
Publicado: (2017)

The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2
por: Bianchi, Nicoletta, et al.
Publicado: (2021)

Tissue Transglutaminase Promotes Drug Resistance and Invasion by Inducing Mesenchymal Transition in Mammary Epithelial Cells
por: Kumar, Anupam, et al.
Publicado: (2010)

Using FLIM-FRET to Measure Conformational Changes of Transglutaminase Type 2 in Live Cells
por: Caron, Nicholas S., et al.
Publicado: (2012)

Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells
por: Kumar, Anupam, et al.
Publicado: (2012)

Design of a glutamine substrate tag enabling protein labelling mediated by Bacillus subtilis transglutaminase
por: Oteng-Pabi, Samuel K., et al.
Publicado: (2018)

Analysis of epithelial–mesenchymal transition markers in psoriatic epidermal keratinocytes
por: Man, Xiao-Yong, et al.
Publicado: (2015)

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
por: Fisher, Matthew L., et al.
Publicado: (2017)

ACTL6A suppresses p21(Cip1) expression to enhance the epidermal squamous cell carcinoma phenotype
por: Shrestha, Suruchi, et al.
Publicado: (2020)

Cytosolic Guanine Nucledotide Binding Deficient Form of Transglutaminase 2 (R580a) Potentiates Cell Death in Oxygen Glucose Deprivation
por: Colak, Gozde, et al.
Publicado: (2011)

Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation
por: Fisher, Matthew L., et al.
Publicado: (2017)

Peptidic Inhibitors and a Fluorescent Probe for the Selective Inhibition and Labelling of Factor XIIIa Transglutaminase
por: Gates, Eric W. J., et al.
Publicado: (2023)

Activated hepatic stellate cells promote epithelial-to-mesenchymal transition in hepatocellular carcinoma through transglutaminase 2-induced pseudohypoxia
por: Ma, Hui, et al.
Publicado: (2018)

Epidermal Transglutaminase (TGase 3) Is the Autoantigen of Dermatitis Herpetiformis
por: Sárdy, Miklós, et al.
Publicado: (2002)

AP1 Transcription Factors in Epidermal Differentiation and Skin Cancer
por: Eckert, Richard L., et al.
Publicado: (2013)

AP1 Factor Inactivation in the Suprabasal Epidermis Causes Increased Epidermal Hyperproliferation and Hyperkeratosis but Reduced Carcinogen-Dependent Tumor Formation
por: Rorke, Ellen A., et al.
Publicado: (2010)

Epidermal Transglutaminase (TGase 3) Is Required for Proper Hair Development, but Not the Formation of the Epidermal Barrier
por: John, Susan, et al.
Publicado: (2012)

Loss of epidermal AP1 transcription factor function reduces filaggrin level, alters chemokine expression and produces an ichthyosis-related phenotype
por: Young, Christina A, et al.
Publicado: (2017)

Genetic Variation in the Epidermal Transglutaminase Genes Is Not Associated with Atopic Dermatitis
por: Liedén, Agne, et al.
Publicado: (2012)

Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition
por: Park, Jeongsook, et al.
Publicado: (2013)

Deletion or Inhibition of Astrocytic Transglutaminase 2 Promotes Functional Recovery after Spinal Cord Injury
por: Elahi, Anissa, et al.
Publicado: (2021)

Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2
por: Jambrovics, Károly, et al.
Publicado: (2020)

Catechol inhibits epidermal growth factor-induced epithelial-to-mesenchymal transition and stem cell-like properties in hepatocellular carcinoma cells
por: Lim, Won-Chul, et al.
Publicado: (2020)

Plasma Membrane Factor XIIIA Transglutaminase Activity Regulates Osteoblast Matrix Secretion and Deposition by Affecting Microtubule Dynamics
por: Al-Jallad, Hadil F., et al.
Publicado: (2011)

Lysyl Oxidase at the Crossroads of Mesenchymal Stem Cells and Epithelial-Mesenchymal Transition
por: Thomas, Clémence, et al.
Publicado: (2013)

Transglutaminase 3: The Involvement in Epithelial Differentiation and Cancer
por: Chermnykh, Elina S., et al.
Publicado: (2020)

Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation
por: Jambrovics, Károly, et al.
Publicado: (2019)

Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer
por: Aguiari, Gianluca, et al.
Publicado: (2022)

Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
por: Ashrafizadeh, Milad, et al.
Publicado: (2020)

Role of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Epithelial–Mesenchymal Transition
por: Kletukhina, Sevindzh, et al.
Publicado: (2019)

Inhibition of Epithelial-Mesenchymal Transition Maintains Stemness in Human Amniotic Epithelial Cells
por: Takano, Chika, et al.
Publicado: (2022)

Targeting transglutaminase 2 mediated exostosin glycosyltransferase 1 signaling in liver cancer stem cells with acyclic retinoid
por: Qin, Xian-Yang, et al.
Publicado: (2023)

Epithelial-mesenchymal transition, cancer stem cells and treatment resistance
por: Dave, Bhuvanesh, et al.
Publicado: (2012)

Links between cancer stem cells and epithelial–mesenchymal transition
por: Wang, Sha-sha, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i0a4jv7171ins7r71dcvjukihf